Cargando…
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
IMPORTANCE: Recurrent Clostridioides difficile infection (CDI) is a debilitating disease leading to poor health-related quality of life (HRQOL), loss of productivity, anxiety, and depression. The potential association of treatment with HRQOL has not been well evaluated. OBJECTIVES: To explore the as...
Autores principales: | Garey, Kevin W., Jo, Jinhee, Gonzales-Luna, Anne J., Lapin, Brittany, Deshpande, Abhishek, Wang, Elaine, Hasson, Brooke, Pham, Sissi V., Huang, Shirley P., Reese, Pat Ray, Wu, Henry, Hohmann, Elizabeth, Feuerstadt, Paul, Oneto, Caterina, Berenson, Charles S., Lee, Christine, McGovern, Barbara, vonMoltke, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887497/ https://www.ncbi.nlm.nih.gov/pubmed/36716031 http://dx.doi.org/10.1001/jamanetworkopen.2022.53570 |
Ejemplares similares
-
19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021) -
Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022) -
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023) -
Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023) -
Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)